Introduction
thrombocytopenia, CLD, TPO-RAs
PROLIFERATION, CHRONIC LIVER DISEASE, THROMBOCYTOPENIA, CLD
Chronic liver disease (CLD) is recognized as a major public health problem worldwide. It is estimated that 1.5 billion people suffer from CLD globally, and its prevalence is increasing [Platelet transfusion is the fastest and gold-standard treatment for thrombocytopenia in patients receiving invasive procedures. Refer to the blood transfusion guidelines to recommend using platelet counts (PLT) < 50 × 10Recently, more clinical evidence has suggested that small-molecule oral thrombopoietin receptor agonists (TPO-RAs) can raise PLT. TPO-RAs was suggested as an effective option to transfusions of platelets in the treatment of CLD with thrombocytopenia in the United States [Lusutrombopag, a novel second-generation oral TPO-RA, can also act on receptors of TPO expressed in megakaryocytes to activate the differentiation and proliferation of megakaryocytes and promote thrombocytopoiesis [